Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of eltrombopag (Revolade) in pediatric chronic immune thrombocytopenia purpura
2017-004082-27Phase 3
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Novartis. Primary endpoint: Safety (frequency of all adverse events).
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2017-004082-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004082-27.